Clinical trials

  • NAPORAFENIB for NRAS-mutant cutaneous melanoma | Unresectable or metastatic cutaneous melanoma
  • SASANLIMAB for Muscle-invasive bladder cancer
  • IMETELSTAT SODIUM for Myelodysplastic syndromes (MDS)
  • Levofloxacin for Community-acquired pneumonia
  • LEVOFLOXACIN for Community-acquired pneumonia
  • 3,4-DIMETHYL-N-(2-PHENYL-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLE-5-CARBOXAMIDE for Advanced systemic mastocytosis
  • SONELOKIMAB for Hidradenitis suppurativa
  • COLCHICINE for Osteoarthritis | Knee osteoarthritis | Hip osteoarthritis
  • EXL01 for Crohn's disease
  • COBOLIMAB for Relapsed/Refractory tumours | Melanoma | Hodgkin lymphoma | Glioma | Osteosarcoma | Hepatic cancer | Rhabdomyosarcoma
  • RAY121 for Immune-mediated necrotizing myopathy | Antiphospholipid syndrome | Behçet’s syndrome | Bullous pemphigoid | Dermatomyositis | Immune thrombocytopenia
  • DB-OTO-5, DB-OTO-3 for Congenital hearing loss due to biallelic OTOF pathogenic variants